NCT06800950View on ClinicalTrials.gov

Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

4,400

Participants

Timeline

Start Date

February 8, 2025

Primary Completion Date

July 15, 2025

Study Completion Date

October 15, 2025

Conditions
Influenza, HumanInfluenza, Human PreventionInfluenza aInfluenza BInfluenza Viral Infections
Interventions
BIOLOGICAL

QIV

Quadrivalent Influenza Virus Split Vaccine containing H1N1, H3N2, Bv, By antigens of 0.5ml for each dose

BIOLOGICAL

QIV Control

Quadrivalent Influenza Virus Split Vaccine containing each type of antigens of 0.5ml for each dose

Trial Locations (3)

Unknown

Xing'an Center for Disease Control and Prevention, Guilin

Yangshuo Center for Disease Control and Prevention, Guilin

Binyang Center for Disease Control and Prevention, Nanning

All Listed Sponsors
collaborator

Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control

OTHER_GOV

lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER